CCL5 deficiency aggravates acute DSS-induced colitis by restricting IL-33-induced formation of Tregs in intestinal tract
Clinical Science · 2026
DOI: 10.1042/cs20256734 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, 2026. Verfasst von Yang Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R., 200127, China. Hauptthemen laut MEDLINE: Interleukin-33, Chemokine CCL5, T-Lymphocytes, Regulatory, Colitis, Ulcerative. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Ulcerative colitis (UC) is a chronic inflammatory disease of the gastrointestinal tract, characterized by ongoing intestinal inflammation, epithelial damage, and mucosal injury. Despite the identification of C-C motif chemokine ligand 5 (CCL5) as a key mediator in UC, the precise mechanisms underlying its role in immune activation and inflammation remain unclear. This study aimed to investigate CCL5 as a critical immune modulator in UC, focusing on its effects on immune cell activation, particularly regulatory T cell (Treg) formation, and the molecular pathways involved in these processes. Using the dextran sulfate sodium salt (DSS)-induced UC model and CCL5 knockout (Ccl5-KO) mice, we demonstrated that CCL5 deficiency exacerbates intestinal inflammation during the acute phase of colitis, partly due to impaired interleukin-33 (IL-33)-induced Treg formation. In addition, we observed a positive correlation between CCL5 expression and forkhead box protein 3 (FOXP3) levels in inflamed colon tissues of UC patients, suggesting a role for CCL5 in Treg regulation. Mechanistically, CCL5 deficiency disrupted the PI3K/Akt/NF-κB signaling pathway, resulting in reduced IL-33 expression, which in turn impaired CD4+ T cell activation and FOXP3+ Treg formation via the JAK1/STAT5 pathway. In vivo rescue experiments confirmed that restoring IL-33 signaling could alleviate inflammation and partially recover Treg function. Collectively, these findings highlight CCL5 as a novel immune modulator of Treg formation and immune responses in UC and suggest that targeting CCL5 may offer a promising therapeutic strategy for managing UC and related inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R., 200127, China.
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R., China.
- Department of General Surgery, Gongli Hospital, 219 Miaopu Road, Pudong New District, Shanghai, P.R., 200135, China.
ORCID-Profile: Ming Zhong
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
Zitieren
APA
Luo, Y., Gong, T. Y., Zhao, Y. H., Li, H., Ye, G. Y., Zhang, Z. Z., Yu, M. H., Zhang, Y., & Zhong, M. (2026). CCL5 deficiency aggravates acute DSS-induced colitis by restricting IL-33-induced formation of Tregs in intestinal tract. Clinical Science. https://doi.org/10.1042/cs20256734
Vancouver
Luo Y, Gong TY, Zhao YH, Li H, Ye GY, Zhang ZZ, et al. CCL5 deficiency aggravates acute DSS-induced colitis by restricting IL-33-induced formation of Tregs in intestinal tract. Clinical Science. 2026. doi:10.1042/cs20256734
BibTeX
@article{Luo2026,
author = {Luo, Yang and Gong, Ting-Yue and Zhao, Yong-Heng and Li, Hao and Ye, Guang-Yao and Zhang, Zi-Zhen and Yu, Min-Hao and Zhang, Yan and Zhong, Ming},
title = {CCL5 deficiency aggravates acute DSS-induced colitis by restricting IL-33-induced formation of Tregs in intestinal tract},
journal = {Clinical Science},
year = {2026},
doi = {10.1042/cs20256734}
}
EUVIMED